Skip to content
Buy This GLP
← Research
Evidence

Does CagriSema Work for Type 2 Diabetes? By 0.16 HbA1c Points

REIMAGINE 2 found a 0.16-point HbA1c difference versus semaglutide 2.4 mg. CagriSema remains investigational in the United States.

Editorial profile: Neil SandersBuy This GLP Editorial Team9 min read
HbA1c change at week 68, percentage pointscagrilintide + semaglutide, 2.4 mg each−1.91semaglutide 2.4 mg alone−1.75Estimated difference: −0.16 points (95% CI −0.27 to −0.05).Participants reporting an adverse event: 86.9% vs 81.2%.

In REIMAGINE 2, CagriSema lowered HbA1c by an additional 0.16 percentage points versus semaglutide 2.4 mg at week 68. The difference was statistically significant. CagriSema remains investigational in the United States [1] [4].

The REDEFINE 1 weight-management trial enrolled participants without type 2 diabetes. REIMAGINE 2 asked a separate question in adults with type 2 diabetes and a BMI of at least 25 whose blood sugar was inadequately controlled on metformin, with or without an SGLT2 inhibitor [1].

REIMAGINE 2 compared CagriSema with semaglutide

Mean baseline HbA1c across the trial was 8.2%. At week 68, estimated reductions were 1.91 percentage points on CagriSema (2.4 mg of each ingredient) and 1.75 points on semaglutide 2.4 mg. The estimated difference was −0.16 points (95% CI −0.27 to −0.05, p=0.0035). These estimates model what would happen if participants stayed on assigned treatment without rescue medication [1].

At least one adverse event was reported by 524 of 603 participants (86.9%) on the higher-dose combination and 491 of 605 (81.2%) on semaglutide 2.4 mg. Gastrointestinal disorders were the most frequently reported category in the active treatment groups [1].

REIMAGINE 3 tested an add-on to basal insulin

REIMAGINE 3 randomized 274 adults whose blood sugar was inadequately controlled on basal insulin, with or without metformin. At week 40, HbA1c fell by an estimated 2.33 and 2.10 percentage points in the two CagriSema groups versus 0.66 points with pooled placebo[2].

All groups continued basal insulin. The trial had no semaglutide-only arm, so it cannot isolate cagrilintide’s contribution. Our guide to low blood sugar with insulin and GLP-1 medicines explains why the background treatment matters. REIMAGINE 3 reported no severe hypoglycemia during the trial, which does not establish the risk for an individual patient [2].

IcoSema is a different combination

IcoSema combines weekly insulin icodec with semaglutide and received EU marketing authorization as Kyinsu in November 2025. Its trials used different comparators from the CagriSema program [5].

Pooling two COMBINE trials with 1,970 adults gave an HbA1c difference of −0.37 percentage points (95% CI −0.95 to 0.21). The I² of 98% indicates very high inconsistency. The trials compared IcoSema with different insulin regimens, which may help explain the difference. Pooled between-group differences favored IcoSema for weight (−6.10 kg) and systolic blood pressure (−2.45 mmHg). Those measures cannot establish whether it prevents heart attacks or strokes [3].

U.S. approval status

As of November 14, 2026, CagriSema remained investigational in the U.S. Novo Nordisk’s December 2025 FDA application was for weight management. The application does not establish approval for weight management or type 2 diabetes [4]. FDA also says cagrilintide cannot be used in compounding under federal law [6].

Frequently asked

Does CagriSema work for type 2 diabetes?
It met its primary endpoint in REIMAGINE 2, cutting HbA1c by 1.91 percentage points against 1.75 on semaglutide alone over 68 weeks, a difference of 0.16 points.
Is it better than semaglutide by itself?
At 68 weeks the estimated HbA1c difference versus semaglutide 2.4 mg was −0.16 percentage points (95% CI −0.27 to −0.05). At least one adverse event was reported by 86.9% versus 81.2% of participants.
Does it help if I am already on insulin?
REIMAGINE 3 added it to basal insulin in 274 adults and HbA1c fell 2.33 percentage points against 0.66 on placebo. The comparator was placebo, so the trial cannot say what cagrilintide adds over semaglutide.
Did these trials measure weight?
Yes. Weight was a prespecified secondary endpoint in REIMAGINE 2. At week 68, estimated weight changes were −14.2% on CagriSema and −10.2% on semaglutide 2.4 mg under the efficacy estimand.
Is CagriSema approved in the United States?
CagriSema remained investigational in the United States as of November 14, 2026. Novo Nordisk filed for weight management in December 2025. The type 2 diabetes trials are a separate program.

Sources

  1. [1] Buse JB, Bajaj HS, Dalskov SM, Donaldson L, Hansen Duus HH, Fabricius TW (2026). Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study The Lancet Diabetes & Endocrinology. PMID 42251859
  2. [2] Rosenstock J, Billings LK, Gajria R, Giorgino F, Johansen NB, Klein KR (2026). Cagrilintide-semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study The Lancet. PMID 42251856
  3. [3] Alper A, et al. (2026). Cardiometabolic outcomes of once-weekly IcoSema in adults with type 2 diabetes: systematic review and meta-analysis of the COMBINE trials Cardiovascular Diabetology - Endocrinology Reports. PMID 42681675
  4. [4] Novo Nordisk (2026). CagriSema REDEFINE 9 results and U.S. regulatory status Novo Nordisk, November 2026. Source
  5. [5] European Medicines Agency (2026). Kyinsu: European Public Assessment Report European Medicines Agency. Source
  6. [6] U.S. Food and Drug Administration (2026). FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss FDA. Source

Where to get it

Price the injectable sellers

The desk lists every seller that publishes an injectable figure, with the advertised price struck against the one a buyer is billed.

Open the price desk →

More in Evidence